Login to Your Account

Other News To Note

Monday, April 16, 2012
• MAP Pharmaceuticals Inc., of Mountain View, Calif., said it submitted a request to the FDA for a meeting to discuss the recent complete response letter (CRL) for Levadex, an orally inhaled formulation of dihydroergotamine for acute migraine. In the CRL, MAP said the FDA did not ask for any additional clinical studies, but raised questions relating to chemistry, manufacturing and controls, as well as issues related to a facility inspection.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription